用于前列腺癌患者PSMA PET显像的Piflufolastat F 18  

Piflufolastat F 18 for PSMA PET imaging in prostate cancer

作　　者：石静天 杨婷[1] 陈超阳[1] 魏然 张玄龄 胡晓娟 周颖[1,2] SHI Jing-tian;YANG Ting;CHEN Chao-yang;WEI Ran;ZHANG Xuan-ling;HU Xiao-juan;ZHOU Ying(Department of Pharmacy,Peking University First Hospital,Beijing 100034,China;Drug Clinical Trial Facility,Peking University First Hospital,Beijing 100034,China;Pharmacy Department,Peking University First Hospital Ningxia Women and Children's Hospital/Ningxia Hui Autonomous Region Maternal and Child Health Hospital,Yinchuan 750001,Ningxia Hui Autonomous Region,China)

机构地区：[1]北京大学第一医院药剂科,北京100034 [2]北京大学第一医院药物临床试验机构,北京100034 [3]北京大学第一医院宁夏妇女儿童医院/宁夏回族自治区妇幼保健院药剂科,宁夏回族自治区银川750001

出　　处：《中国临床药理学杂志》2024年第12期1835-1838,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：2021-05-27,美国食品药品监督管理局(FDA)正式批准美国Lantheus公司的Piflufolastat F 18注射液(18F标记的诊断显像剂,商品名:PYLARIFY■)用于前列腺癌患者前列腺特异性膜抗原(PSMA)阳性病变的正电子发射型计算机断层显像(PET),以便更加准确地识别前列腺癌的疑似转移或复发。Piflufolastat F 18被FDA批准用于2种适应证:第1个是对首诊疑似前列腺癌患者的初步分期;第2个是鉴别前列腺癌生化复发患者病灶的再分期。On May 27, 2021, the U.S. Food and Drug Administration(FDA) officially approved Lantheus' PYLARIFY■(Piflufolastat F 18,^(18)F-labeled imaging agent), which can be used for positron emission computed tomography(PET) of prostate-specific membrane antigen(PSMA)-positive lesions in prostate cancer patients to accurately identify prostate cancer with suspected metastasis or recurrence. Piflufolastat F 18 is approved by FDA for two indications. The first is the initial staging for suspected metastatic lesions in men with newly diagnosed prostate cancer. The second is restaging, with the goal of identifying lesions in the setting of biochem ical recurrence.

关 键 词：Piflufolastat F 18 前列腺癌 前列腺特异性膜抗原 正电子发射型计算机断层显像 

分 类 号：R981[医药卫生—药品]